Company Overview and News
Have you been paying attention to shares of Harsco (HSC - Free Report) ? Shares have been on the move with the stock up 18.1% over the past month. The stock hit a new 52-week high of $29.15 in the previous session. Harsco has gained 53.6% since the start of the year compared to the -3.7% move for the Zacks Industrial Products sector and the 26.6% return for the Zacks Industrial Services industry.
AVY BDC HSC ASHTY ASHTF AHT VRA
Investors focused on the Industrial Products space have likely heard of Harsco (HSC - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Industrial Products peers, we might be able to answer that question.
Chicago, IL – September 12, 2018 - Stocks in this week’s article are Harsco Corp. (HSC - Free Report) , The Hanover Insurance Group, Inc. (THG - Free Report) , Avaya Holdings Corp. (AVYA - Free Report) , Ternium S.A. (TX - Free Report) and eXp World Holdings, Inc. (EXPI - Free Report) .
RBBN THG AVYA HSC EXPI CSL THGA
Coverage initiation on a stock by analyst(s) plays a key role in interpreting information pertaining to capital markets, thereby creating value for investors. Lack of information creates inefficiencies that might trigger misinterpretation of stocks (over- or under-valued). In fact, coverage initiation usually depicts increased investor inclination. Investors, on their part, often assume that there is something in the stock that has attracted analyst attention.
THG AVYA HSC EXPI THGA
Chicago, IL – September 11, 2018 - Stocks in this week’s article are Commercial Vehicle Group Inc. (CVGI - Free Report) , Enova International Inc. (ENVA - Free Report) , Luxfer Holdings PLC (LXFR - Free Report) , Conn's, Inc. (CONN - Free Report) and Harsco Corp. (HSC - Free Report) .
CVGI BRK.A HSC LXFR CSL CONN ENVA ALK
CHARLOTTE, N.C., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Harsco Corporation’s (NYSE:HSC) railway track maintenance division, Harsco Rail, announced today it has been awarded a contract by the Land Transport Authority of Singapore (LTA). The LTA focuses on planning, designing, building and maintenance of Singapore’s land transport systems and infrastructure.
Chicago, IL – August 24, 2018 - Stocks in this week’s article include: Commercial Vehicle Group Inc. (CVGI - Free Report) , Harsco Corp. (HSC - Free Report) , Luxfer Holdings PLC (LXFR - Free Report) , QuinStreet, Inc. (QNST - Free Report) and Triton International Ltd. (TRTN - Free Report) .
CVGI HSC DECK LXFR SF SFN WCG TRTN BIG ON QNST NWL CBG HII SFB CBRE
Businesses churning out high profits are sought by one and all. In order to gauge the extent of profit, there is no better metric than net profit margin. Net profit margin demonstrates the financial strength of a company. It determines the efficiency of a company in deploying its resources, making it the best metric to measure its profitability. Net Profit Margin = Net profit/Sales * 100. In simple terms, net profit is the amount a company retains after deducting all costs, interest, depreciation, taxes and other expenses.
CVGI SOJA STZ.B SO HSC LXFR STZ TRTN QNST
Have you been paying attention to shares of Harsco (HSC - Free Report) ? Shares have been on the move with the stock up 10.2% over the past month. HSC hit a new 52-week high of $26.8 in the previous session. Harsco has gained 42.4% since the start of the year compared to the -4.9% move for the Zacks Industrial Products sector and the 29.9% return for the Zacks Industrial Services industry.
AVY BDC CSWI HSC SCSC NSIT
We believe that Harsco Corporation (HSC - Free Report) is a solid choice for investors seeking exposure in the industrial services space. The stock, with roughly $2-billion market capitalization, was upgraded to a Zacks Rank #1 (Strong Buy) on Aug 15. Moreover, the stock’s investment appeal is accentuated by a favorable VGM Score of A. The company delivered better-than-expected results in the last four quarters, with an average positive earnings surprise of 17.
[DXPE] DXPE HSC AIMC CFX
Peroxisome Proliferator-Activated Receptor isotypes, PPAR-α, PPAR-δ/β and PPAR-γ are ligand-activated nuclear receptors discovered in 1990, are highly prevalent in metabolically active issues, liver, kidney and intestine.
HSC AP CBAY
Chicago, IL – August 8, 2018 - Stocks in this week’s article include: Turtle Beach Corp. (HEAR - Free Report) , PetroChina Company Limited (PTR - Free Report) , Harsco Corporation (HSC - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Triton International Limited (TRTN - Free Report) .
FOX HSC STLD WCG TRTN BIG ON MTH SFM ARW HEAR MS FOXA
ArcBest Corporation (ARCB - Free Report) : This company that provides freight transportation services and integrated logistics solutions has seen the Zacks Consensus Estimate for its current year earnings increasing 4.4% over the last 60 days.
ELY HSC ARCB CRAI CATM
The primary motive of any investor is to generate maximum returns. Thus, investors are always on the lookout for companies that are raking in huge profits. Net profit margin is the most effective way to measure a company’s profitability. A proper analysis of the same reveals how well a company is functioning and the headwinds confronting it. Net Profit Margin = Net profit/Sales * 100. In simple terms, net profit is the amount a company retains after deducting all costs, interest, depreciation, taxes and other expenses.
HSC AMT HEAR TRTN GTLS
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to HSC / Harsco Corp. on message board site Silicon Investor.
as of ET